Mytheos Holt

Mytheos Holt is Senior Fellow in the Freedom to Innovate at the Institute for Liberty. He has held positions at the R Street Institute, Mair Strategies, TheBlaze, and National Review. He also worked as a speechwriter for U.S. Sen. John Barrasso  His writing on video games has been featured at TheBlaze, Gamesided, the Escapist, and the Federalist. He hails originally from Big Sur, California, but currently lives in Arlington, Virginia. Yes, Mytheos is his real name.

TC Heartland Is Not a Magic Bullet

 

Early this week, the Supreme Court dropped yet another historic ruling on the subject of patent law. In fact, not only was the decision historic, but it was historically correct. That case, TC Heartland v. Kraft, a seemingly innocuous dispute over flavored drink mixes, amounts to a sweeping rejection of the legal strategy employed by […]

Continue Reading

Blue Cross Blows Big Pharma’s Cover

 

With healthcare reform now back on the docket in the U.S. Senate, liberals are crying bloody murder over the purely hypothetical costs to the insured that exist entirely in their heads. But they’re not wrong about one thing: healthcare is too expensive, and the fact that people try to lay the costs of it almost […]

Continue Reading

When Patents Are Bad, Property Rights Suffer

 

While the debate over patent reform has faced something of a lull, with multiple high-profile policy issues currently eating up a large chunk of Congress’s time, this lack of attention should distract nobody. The issue is still alive and well and is very much something that both sides of the aisle should be concerned about, […]

Continue Reading

The CREATES Act Is Back

 

This past Thursday, April 27, a major piece of legislation that deserves far more attention made its debut in the Senate. I refer to the “Creating and Restoring Equal Access to Equivalent Samples Act of 2017,” abbreviated as the CREATES Act of 2017. While this bill originally was scheduled to debut back in February, apparently […]

Continue Reading

Patent Trolls Don’t Care About the Law

 

Defense of today’s patent system can be a difficult job. At its best, the system can encourage innovation, protect the sacred rights of inventors, and do it highly effectively. At its worst, it falls prey to loopholes and day-to-day issues that make it fertile ground for abuse and negligence. Not to mention, it arguably is […]

Continue Reading

How Big Pharma Exploits the Cancer Drug Market

 

With another day, another headline arrives revealing the arrogant, out-of-touch nature of the pharmaceutical industry. Fortunately, this time, the outrage arrives from overseas. Specifically, the UK Independent reports that Aspen Pharmaceuticals, which you might remember for such hits as economically blackmailing the Italian government via its monopoly power over certain drugs, is up to its old tricks again. This time, […]

Continue Reading

Airbnb Doesn’t Want the Law to Apply to Them

 

Scratch just beneath the surface of any of the multiple lawless stays on President Trump’s travel ban, and you will find one thing in common: certain tech companies back all of them. The leading example, so far, has been Airbnb, which, incredibly, signed on to both the lawsuit against the travel ban in its original […]

Continue Reading

Pharma’s Bogus Case Against the CREATES Act

 

Big Pharma’s trash fire of lies seems to rise ever higher each day. On one level, this is thoroughly unsurprising. For the first time in an eon, one of D.C.’s most protected industries is feeling some heat. Egged on by a price-skeptical president, bipartisan coalitions in Congress have formed around the cause of lowering drug […]

Continue Reading

Airbnb and Property Rights Don’t Go Together

 

For defenders of the so-called “sharing economy,” companies like the housing-sharing website Airbnb and the ride-sharing app Uber are near-sacred. In the case of Uber, “sharing” enthusiasts argue that the company is a symbol of disruption against an anticompetitive status quo. In the case of Airbnb, it offers a similar defense, with the added point […]

Continue Reading

The Free Market Is Coming for Pharma

 

Scratch a “conservative” defender of the pharmaceutical industry on the topic of drug prices, and you’ll generally hear an argument formulated something like the following: “High drug prices are just the free market at work. Who are we to judge how much a piece of life-saving technology is worth?” Were the market for drugs truly […]

Continue Reading





Send this to a friend